Impel Pharmaceuticals Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product…
Year: 2022
Rain Therapeutics to Participate in H.C. Wainwright’s 3rd Annual Precision Oncology Virtual Conference
NEWARK, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”) a…
PepGen Announces Positive Preclinical Data for PGN-EDO53, PGN-EDO45 and PGN-EDO44, Three Novel Duchenne Muscular Dystrophy Candidates
PGN-EDO53 NHP Exon Skipping, PGN-EDO45 and PGN-EDO44 Exon Skipping in Wild-Type Human Myoblasts High levels…
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2022 Financial Results
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the pivotal…
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
FDA clearance of two new INDs: PRT3789 (First-in-class Selective SMARCA2 degrader) and PRT3645 (next generation…
Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for…
Opus Genetics Sponsors Uni-Rare Natural History Study for People with Inherited Retinal Diseases
Largest study to date to characterize natural history of rare retinal diseases RESEARCH TRIANGLE PARK,…
PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
Seeking guidance from FDA to proceed towards a Phase 3 clinical study of KETARX™ (ketamine)…
SELLAS Life Sciences Announces Update on Phase 3 REGAL Clinical Trial Evaluating Lead Asset, Galinpepimut-S, in Acute Myeloid Leukemia
– Overall Survival Observed in Pooled Patient Data to Date Leads to Changes in Statistical…
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
WALTHAM, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) — Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical…
4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)
Cohort 1 patients (n=5) received a single intravitreal injection of 4D-150 (3E10 vg/eye); these patients…
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
SAN DIEGO and TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Aptose Biosciences Inc. (“Aptose”) (NASDAQ:…
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update
Announced preliminary PDS0101 efficacy and safety data for Phase 2 clinical studies led by The…
Abeona Therapeutics Reports Third Quarter 2022 Financial Results
Following positive topline data from Phase 3 VIITAL™ study of EB-101 with both co-primary endpoints…
Windtree Therapeutics Reports Third Quarter 2022 Financial Results and Provides Key Business Updates
WARRINGTON, Pa., Nov. 14, 2022 (GLOBE NEWSWIRE) — Windtree Therapeutics, Inc. (NasdaqCM: WINT), a biotechnology…
Zynerba Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Highlights
Enrollment continues in RECONNECT, a confirmatory pivotal Phase 3 trial of Zygel™ in patients with…
Avicanna Reports Q3 2022 Financial Statement
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES…
Mindset Pharma Presents Poster at Neuroscience 2022 Highlighting Preclinical Data on MSP-1014, its Psilocybin-like Lead Drug Candidate
Tolerability of MSP-1014 May Be Superior to Psilocybin TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) —…
Cronos Group Appoints James Holm as Chief Financial Officer
TORONTO, Nov. 14, 2022 (GLOBE NEWSWIRE) — Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”…
Alimera Sciences Announces Third Quarter 2022 Financial Results
Consolidated Net Product Revenue of $13.6 Million, up 11% vs. Third Quarter of 2021 Net…